Sun Pharma launches diabetes drug metformin in the US

Sun Pharmaceutical Industries  said it has launched the glucose regulating drug  metformin hydrochloride in the United States.

The tablets in two strengths — 500 mg and 1000 mg —  have an addressable market size  of around $443 million, the company said, quoting IQVIA.

Metformin hydrochloride is sold in the US by Santarus Inc under the brand name Glumetza HCl extended release tablets.

Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra.

It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) primarily in India and the United States.

The company offers formulations in various therapeutic areas, such as cardiology,  psychiatry,  neurology, gastroenterology and diabetology.

The company’s acquisition of Ranbaxy four years ago made it the largest pharma company in India and the largest Indian pharma company in the US.